Suppr超能文献

涉及色素沉着兔局部应用噻吗洛尔的眼部药物相互作用。

Ocular drug interactions involving topically applied timolol in the pigmented rabbit.

作者信息

Luo A M, Sasaki H, Lee V H

机构信息

University of Southern California School of Pharmacy, Department of Pharmaceutical Sciences, Los Angeles 90033.

出版信息

Curr Eye Res. 1991 Mar;10(3):231-40. doi: 10.3109/02713689109003445.

Abstract

The objective of this study was to determine whether the ocular and systemic absorption of topically applied timolol in the pigmented rabbit was significantly affected by the coadministration with other eye medications, including pilocarpine, epinephrine, their prodrugs, phenylephrine, tetracaine, and proparacaine. Twenty-five microliters of 0.65% timolol maleate solutions, both in the presence and absence of a second drug, were instilled to the pigmented rabbit eye. Timolol concentrations in anterior segment tissues were monitored at 30 and 90 min, and the time course of timolol concentration in plasma was monitored over 120 min. All coadministered drugs except proparacaine reduced intraocular timolol concentrations by varying extents depending on the sampling time, while increasing the timolol concentrations in the conjunctiva and sclera. In addition, all coadministered drugs, except pilocarpine, tetracaine, and proparacaine, reduced the systemic absorption of timolol by an average of about 50%. A plausible explanation for the simultaneous reduction in ocular and systemic timolol absorption is changes in tear turnover rate, protein secretion, and binding of timolol to tear proteins, rather than changes in corneal and perhaps conjunctival and nasal permeability, elicited by the second drug. Vasoconstriction on the conjunctival and nasal mucosae is an additional factor possibly contributing to the reduction in systemic timolol absorption by epinephrine, its prodrug, phenylephrine, and perhaps the pilocarpine prodrug. The clinical implication of the above findings is that before instituting combination or multiple drug therapy the possibility of changes in ocular and systemic absorption of the first drug by the second drug must be considered.

摘要

本研究的目的是确定在有色兔中,局部应用噻吗洛尔时,与其他眼部药物(包括毛果芸香碱、肾上腺素、它们的前体药物、去氧肾上腺素、丁卡因和丙美卡因)合用是否会显著影响其眼部和全身吸收。在有色兔眼中滴入25微升0.65%的马来酸噻吗洛尔溶液,分别在有和没有第二种药物存在的情况下进行。在30分钟和90分钟时监测前节组织中的噻吗洛尔浓度,并在120分钟内监测血浆中噻吗洛尔浓度的时间进程。除丙美卡因外,所有合用药物均根据采样时间不同程度地降低了眼内噻吗洛尔浓度,同时增加了结膜和巩膜中的噻吗洛尔浓度。此外,除毛果芸香碱、丁卡因和丙美卡因外,所有合用药物均使噻吗洛尔全身吸收平均降低约50%。眼内和全身噻吗洛尔吸收同时降低的一个合理原因是泪液周转率、蛋白质分泌以及噻吗洛尔与泪液蛋白质结合的变化,而不是第二种药物引起的角膜以及可能的结膜和鼻腔通透性的变化。结膜和鼻粘膜的血管收缩是肾上腺素、其前体药物、去氧肾上腺素以及可能的毛果芸香碱前体药物导致噻吗洛尔全身吸收降低的另一个可能因素。上述发现的临床意义在于,在开始联合或多种药物治疗之前,必须考虑第二种药物改变第一种药物眼部和全身吸收的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验